Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and commercializing innovative therapies to treat serious diseases
With an emphasis on cystic fibrosis, Vertex has pioneered groundbreaking treatments that significantly improve the lives of patients with this genetic disorder. In addition to its work in cystic fibrosis, the company is exploring potential therapies for other rare diseases, including pain management and beta-thalassemia. Vertex is dedicated to advancing scientific research and collaborating with the global medical community to bring new solutions to unmet medical needs.
Markets were flat but positive in an initial trading day for a new week, basically shrugging off whatever warning signs may have been considered regarding President Trump’s 25% steel tariff headline this morning.
Biotech company Vertex Pharmaceuticals (NASDAQVRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the full year’s revenue to be around $11.88 billion, close to analysts’ estimates. Its non-GAAP profit of $3.98 per share was 1% below analysts’ consensus estimates.
